Reference only. Testing guidance shown is derived from published clinical guidelines and regulatory sources. It does not constitute a clinical recommendation for any individual patient. Payer coverage information is a general summary and may not reflect current policy or individual benefit design. Full disclaimer
Solid TumorICD-10: C18-C20
Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer worldwide. Molecular profiling — particularly RAS/RAF mutational status, MSI-H/dMMR status, HER2 amplification, and NTRK fusions — directly guides first-line and subsequent therapy selection. Comprehensive biomarker testing is recommended at diagnosis for all stages with metastatic potential.
Select Subtype — 2 subtypes with recommendations
Colon Adenocarcinoma
→Adenocarcinoma arising in the colon (cecum through sigmoid). RAS/RAF mutational status is required before initiating anti-EGFR therapy. MSI-H/dMMR status qualifies for immune checkpoint inhibitor monotherapy.
ICD-10: C18.9
Rectal Adenocarcinoma
→Adenocarcinoma arising in the rectum. Shares biomarker testing priorities with colon cancer; HER2 testing increasingly recommended given emerging antibody-drug conjugate therapies.
ICD-10: C20